A new federal strategy — not a completed reform
HHS announced the Kidney Care National Plan on October 20 as a department-wide approach to chronic kidney disease. It builds on earlier federal work, including a 2019 executive order promoting kidney health, home dialysis and transplantation. The plan proposes to shift attention toward preventing kidney failure, expanding patient choice and improving accountability throughout the kidney-care system.
Those are substantial policy objectives, but a plan is different from a final regulation or a demonstrated clinical result. Each change will require decisions by agencies, providers, insurers or lawmakers, depending on the action. The practical test will be whether patients experience earlier diagnosis, better outcomes, more choices and safe care at sustainable cost.
Why prevention is a central priority
HHS estimates that about 37 million U.S. adults have chronic kidney disease. Its fact sheet says about 87% of those affected do not know they have the condition. Because the disease can remain largely symptomless until serious damage occurs, opportunities to slow progression may be missed.
The plan proposes evidence reviews and research to improve screening, diagnostics and therapies. It highlights at-risk people, including those with diabetes, hypertension or a family history of kidney disease. That does not mean every American needs the same test at the same frequency. The value, affordability and consequences of screening policies depend on patient risks and the supporting medical evidence.
Dialysis competition and care at home
Dialysis performs some filtering functions when kidneys fail. HHS says two large companies control roughly 74% of the U.S. dialysis market, a figure the department uses to illustrate concentration. Concentration can restrict local patient choice, but market share alone does not establish that a particular price or outcome is caused by anticompetitive conduct.
The agency says it will examine regulatory and reimbursement barriers that may limit new providers, home dialysis and technological innovation. Advocates of reform argue that removing unnecessary barriers could widen access and encourage better treatment options. Others emphasize the importance of quality standards and oversight because dialysis patients can be especially vulnerable to errors or unsafe conditions. A sound policy must consider competition and patient safety together.
Transplantation and patient protections
The third pillar focuses on the organ-transplant system. HHS says it wants stronger safety, transparency and accountability while expanding access to both living and deceased-donor transplants. It also describes a National Transplant Expansion Strategy.
There are tradeoffs to manage. Expanding access can improve lives and potentially reduce years of dialysis, but transplantation requires careful matching, lifelong follow-up and protection of living donors. Oversight systems must remain credible, particularly where organ procurement and waiting-list fairness are concerned.
What the administration says — and what remains uncertain
HHS Secretary Robert F. Kennedy Jr. framed the plan as an effort to move care earlier in the disease process and improve patient choice. The administration regards existing regulation and industry concentration as barriers to innovation. These are the department's stated policy judgments, not independent proof that every rule under review is unnecessary or that market changes will automatically improve health outcomes.
The plan deserves evaluation on measurable benchmarks: how many people are diagnosed earlier, the quality of dialysis and transplantation, geographic access, clinical outcomes, and overall costs to patients and public programs. As of the announcement, those future outcomes could not yet be measured.
